BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00

BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by HC Wainwright from $90.00 to $100.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($1.69) EPS.

Several other research firms have also issued reports on BBIO. JPMorgan Chase & Co. raised their price target on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Sanford C. Bernstein initiated coverage on shares of BridgeBio Pharma in a research note on Thursday, December 11th. They issued an “outperform” rating and a $94.00 target price for the company. TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Morgan Stanley started coverage on BridgeBio Pharma in a research note on Tuesday, January 6th. They set an “overweight” rating and a $96.00 price target on the stock. Finally, Truist Financial raised their price objective on BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Twenty-two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.05.

BridgeBio Pharma Trading Down 4.3%

Shares of BridgeBio Pharma stock opened at $70.72 on Tuesday. The company’s fifty day simple moving average is $75.66 and its 200-day simple moving average is $63.84. The company has a market cap of $13.63 billion, a price-to-earnings ratio of -16.92 and a beta of 1.13. BridgeBio Pharma has a 1 year low of $28.33 and a 1 year high of $84.94.

Insider Activity

In other news, CFO Thomas Trimarchi sold 13,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Maricel Apuli sold 510 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total transaction of $37,898.10. Following the completion of the transaction, the chief accounting officer owned 123,945 shares of the company’s stock, valued at $9,210,352.95. This trade represents a 0.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 176,121 shares of company stock worth $13,009,631 in the last quarter. 18.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On BridgeBio Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of BBIO. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in BridgeBio Pharma in the second quarter worth $25,000. Aster Capital Management DIFC Ltd bought a new position in shares of BridgeBio Pharma in the third quarter valued at about $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma during the 3rd quarter worth about $34,000. Jones Financial Companies Lllp bought a new stake in BridgeBio Pharma during the 1st quarter worth about $35,000. Finally, First Horizon Corp bought a new stake in BridgeBio Pharma during the 3rd quarter worth about $36,000. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.